Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
The Brain as a Target of Inflammatory Processes
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
“Human Medicines” page
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Rituximab does not reset defective early B cell tolerance checkpoints.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Autoantibodies and pain.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development
Webinar: "Seeking Best Practices in Classifier Construction and Testing"
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Dimethylfumarate Impairs Neutrophil Functions.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.

Pages